Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

ICPO Foundation Partners With Leading Pharmaceutical Company to Fund 130 Stipends to Professionals for the Academy's Online Education Program in the Field of Radiomolecular Precision Oncology (RPO) in the Asia Pacific Region.

Today, the Academy for Theranostics, a transformative initiative developed by the International Centers for Precision Oncology (ICPO) Foundation, announced that ADACAP (Advanced Accelerator Applications International S.A), a Novartis company, has signed a grant agreement to fund 130 stipends for the Academy's online education program. The primary beneficiaries of the ICPO Academy for Theranostics include clinicians, researchers, physicists, radiochemists, as well as nurses and technologists, all dedicated to integrating Radiomolecular Precision Oncology (RPO) into patient treatment. RPO brings a spectacular improvement in cancer care while today’s global demand largely exceeds patient access. Standardized education is key to bridge this gap. Radiotheranostics has the power to offer novel patient-focused precision oncology treatments according to the principle: “We treat what we see and see what we treat”. The ICPO Foundation, through its global Community, will identify promising recipients for the Novartis stipends, enabling young professionals to access world-class education and laying the ground for their future in theranostics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240118004350/en/

ICPO ACADEMY  FOR THERANOSTICS powered by the ICPO FOUNDATION Global Community (Photo: Business Wire)

ICPO ACADEMY FOR THERANOSTICS powered by the ICPO FOUNDATION Global Community (Photo: Business Wire)

Cancer remains a pressing global issue, impacting millions of individuals annually. In 2020, the World Health Organization (WHO) reported a staggering 9.9 million deaths attributed to cancer. In response, the Radiomolecular Precision Oncology (RPO) approach, which empowers personalized treatments has gained remarkable significance. Nevertheless, the broad adoption of Radiomolecular Precision Oncology faces substantial hurdles due to a critical shortage of skilled professionals. Thus, the imperative of nurturing and guiding young talents in this domain has never been more pronounced. It is therefore of great importance to set standards in a rapidly developing field where the increase in patient access must be controlled qualitatively on a global level.

The ICPO Academy for Theranostics addresses this imperative by offering an extensive online educational program developed by the ICPO Foundation. This online program, supported by a global community of experts, encompasses over 50 hours of content, led by more than 30 leading experts from medicine, science, technology and patient care. The content is accessible in multiple languages. The primary objective of this program is to disseminate knowledge in Radiomolecular Precision Oncology, thereby improving patient outcomes with radiopharmaceutical therapies.

The certification process for the online program is structured to ensure that participants thoroughly understand the key learning points of each teaching unit. Each pillar, i.e. medical, physics, chemistry or nursing, of the program is divided into multiple teaching units. After completing a teaching unit, participants are required to take a multiple-choice test to assess their comprehension of the material. To successfully complete a teaching unit, participants must answer at least 80 percent of the questions correctly. This ensures that they have a solid grasp of the knowledge presented.

Odile Jaume, CEO of ICPO Foundation, conveyed her deep enthusiasm for this collaboration, stating “The global expansion of the Academy for Theranostics, with a particular emphasis on the Asia-Pacific region, is central to the strategic initiatives. Our aim is to extend the benefits of theranostics and cutting-edge cancer treatments to one of the most severely impacted regions to enhance the care access and quality of life for patients in this region.”

Udo Vetter, Chairman of ICPO Board of Trustees, is pleased about the continuation of the pilot project in China and explains “Over 700 users from more than 300 hospitals in China took part in our program in 2023, 400 of whom were actively involved in learning. Impressively, more than 340 participants obtained their final certificates within just 8 weeks. We believe that Novartis' commitment to the industry will serve as a catalyst, encouraging others to follow suit.”

About ICPO Foundation

The International Centers for Precision Oncology Foundation (ICPO) is a non-profit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Recognizing a paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO Foundation is helping to build momentum to scale global patient access to Radiomolecular Precision Oncology to support this shift. To scale patient access, the ICPO Foundation aims to develop an international network of physical diagnostic and therapeutic Centers for Precision Oncology organized in a Social Franchise model based on shared know-how, certified education with so called Academy, and design and process standardization that enables best clinical practice globally. Furthermore, it is the ICPO Foundation’s objective to empower its Centers by embedding them in a highly inclusive Community that spearheads its model and lives up to the Precision Oncology promise, by making it available to all patients in need, irrespective of country or social status.

Learn more at www.icpo.foundation

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.